CIK 1819257
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 93.79% | 26 |
| Unclassified | 2.47% | 1 |
| Health Care Providers & Services | 1.92% | 1 |
| Life Sciences Tools & Services | 1.82% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | Health Care | 40.13% |
| 2 | ARGX | Argenx SE | Health Care | 4.76% |
| 3 | INSM | INSMED Inc | Health Care | 4.57% |
| 4 | ONC | BeOne Medicines Ltd. | Health Care | 4.24% |
| 5 | COGT | Cogent Biosciences, Inc. | Health Care | 4.07% |
| 6 | MIRM | Mirum Pharmaceuticals, Inc. | Health Care | 3.77% |
| 7 | BLTE | BELITE BIO, INC | Health Care | 3.30% |
| 8 | LEGN | Legend Biotech Corp | Health Care | 3.18% |
| 9 | NKTR | NEKTAR THERAPEUTICS | Health Care | 2.68% |
| 10 | DBVT | DBV Technologies S.A. | Health Care | 2.57% |
28/29 names classified · sector 97.5% of weight · industry 97.5% · mkt cap 83.9%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 97.5% of the book is sector-classified (unclassified names shown, never dropped).
Only 6% of book weight classified — the grid is NOT representative of the whole book.
Classified: 6.0% of book weight (2/29 names) · unclassified 94.0%: ROIV, ARGX, INSM, COGT, MIRM, BLTE, LEGN, NKTR, DBVT, PHVS +17 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | ROIVROIVANT SCIENCES LTD | 8,166,047 | $226M | 40.1% | HOLD |
| 2 | ARGXARGENX SE | 36,718 | $27M | 4.8% | ADD 41% |
| 3 | INSMINSMED INC | 157,500 | $26M | 4.6% | TRIM −41% |
| 4 | ONCBEONE MEDICINES LTD | 80,542 | $24M | 4.2% | ADD 16% |
| 5 | COGTCOGENT BIOSCIENCES INC | 596,000 | $23M | 4.1% | ADD 88% |
| 6 | MIRMMIRUM PHARMACEUTICALS INC | 230,000 | $21M | 3.8% | TRIM −23% |
| 7 | BLTEBELITE BIO INC | 116,684 | $19M | 3.3% | NEW |
| 8 | LEGNLEGEND BIOTECH CORP | 990,000 | $18M | 3.2% | NEW |
| 9 | NKTRNEKTAR THERAPEUTICS | 210,000 | $15M | 2.7% | NEW |
| 10 | DBVTDBV TECHNOLOGIES S A | 693,534 | $14M | 2.6% | ADD 93% |
| 11 | PHVSPHARVARIS N V | 493,000 | $14M | 2.5% | TRIM −9% |
| 12 | ABVXABIVAX SA | 121,245 | $14M | 2.4% | TRIM −7% |
| 13 | XENEXENON PHARMACEUTICALS INC | 227,000 | $13M | 2.3% | ADD 66% |
| 14 | CELCCELCUITY INC | 95,000 | $11M | 1.9% | TRIM −21% |
| 15 | EYPTEYEPOINT INC | 795,000 | $10M | 1.8% | HOLD |
| 16 | MRKMERCK & CO INC | 80,000 | $10M | 1.7% | NEW |
| 17 | ARQTARCUTIS BIOTHERAPEUTICS INC | 400,645 | $9M | 1.7% | ADD 91% |
| 18 | ALLOALLOGENE THERAPEUTICS INC | 3,450,000 | $8M | 1.5% | TRIM −30% |
| 19 | KYMRKYMERA THERAPEUTICS INC | 100,000 | $8M | 1.5% | TRIM −28% |
| 20 | DNTHDIANTHUS THERAPEUTICS INC | 93,882 | $8M | 1.4% | TRIM −37% |
| 21 | ELVNENLIVEN THERAPEUTICS INC | 200,000 | $8M | 1.4% | TRIM −35% |
| 22 | CATXPERSPECTIVE THERAPEUTICS INC | 1,625,000 | $7M | 1.2% | ADD 43% |
| 23 | DFTXDEFINIUM THERAPEUTICS INC COM SHS | 331,000 | $6M | 1.1% | NEW |
| 24 | HROWHARROW INC | 165,209 | $6M | 1.0% | ADD 2250% |
| 25 | TARAPROTARA THERAPEUTICS INC | 1,030,846 | $5M | 1.0% | NEW |
| 26 | CTMXCYTOMX THERAPEUTICS INC. | 1,085,790 | $5M | 0.9% | NEW |
| 27 | RCUSARCUS BIOSCIENCES INC | 195,000 | $4M | 0.7% | ADD 15% |
| 28 | ASMBASSEMBLY BIOSCIENCES INC | 136,315 | $4M | 0.7% | ADD 7% |
| 29 | SYRESPYRE THERAPEUTICS INC | 1,000 | $50,440 | 0.0% | TRIM −99% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| ROIVROIVANT SCIENCES LTD | 12.5M | 12.5M | 12.5M | 12.5M | 8.2M | 8.2M | $226M |
| ARGXARGENX SE | — | — | 29K | 16K | 26K | 37K | $27M |
| INSMINSMED INC | 307K | 330K | 359K | 326K | 267K | 158K | $26M |
| ONCBEONE MEDICINES LTD | — | — | — | — | 69K | 81K | $24M |
| COGTCOGENT BIOSCIENCES INC | — | — | — | — | 317K | 596K | $23M |
| MIRMMIRUM PHARMACEUTICALS INC | 65K | 116K | 113K | 104K | 299K | 230K | $21M |
| BLTEBELITE BIO INC | — | — | — | — | — | 117K | $19M |
| LEGNLEGEND BIOTECH CORP | — | — | — | — | — | 990K | $18M |
| NKTRNEKTAR THERAPEUTICS | — | — | — | — | — | 210K | $15M |
| DBVTDBV TECHNOLOGIES S A | — | — | — | — | 359K | 694K | $14M |
| PHVSPHARVARIS N V | 208K | 245K | 244K | 345K | 543K | 493K | $14M |
| ABVXABIVAX SA | — | — | — | 152K | 130K | 121K | $14M |
| XENEXENON PHARMACEUTICALS INC | — | — | — | — | 137K | 227K | $13M |
| CELCCELCUITY INC | — | — | — | 100K | 120K | 95K | $11M |
| EYPTEYEPOINT INC | 1.4M | 1.5M | 1.4M | 1.0M | 780K | 795K | $10M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
